CN105377897A - Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 - Google Patents

Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 Download PDF

Info

Publication number
CN105377897A
CN105377897A CN201480030178.9A CN201480030178A CN105377897A CN 105377897 A CN105377897 A CN 105377897A CN 201480030178 A CN201480030178 A CN 201480030178A CN 105377897 A CN105377897 A CN 105377897A
Authority
CN
China
Prior art keywords
cells
car
cell
transduced
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480030178.9A
Other languages
English (en)
Chinese (zh)
Inventor
余建华
C·霍夫梅斯泰
储剑虹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Priority to CN202210255676.XA priority Critical patent/CN115028735A/zh
Publication of CN105377897A publication Critical patent/CN105377897A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CN201480030178.9A 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 Pending CN105377897A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210255676.XA CN115028735A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819141P 2013-05-03 2013-05-03
US61/819,141 2013-05-03
US201361876492P 2013-09-11 2013-09-11
US61/876,492 2013-09-11
PCT/US2014/036684 WO2014179759A1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210255676.XA Division CN115028735A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Publications (1)

Publication Number Publication Date
CN105377897A true CN105377897A (zh) 2016-03-02

Family

ID=51844005

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210255676.XA Pending CN115028735A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CN201480030178.9A Pending CN105377897A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210255676.XA Pending CN115028735A (zh) 2013-05-03 2014-05-02 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞

Country Status (15)

Country Link
US (3) US10358494B2 (enExample)
EP (2) EP2992020B1 (enExample)
JP (3) JP6856188B2 (enExample)
KR (1) KR102098985B1 (enExample)
CN (2) CN115028735A (enExample)
AU (2) AU2014259675B2 (enExample)
BR (1) BR112015027567B1 (enExample)
DK (1) DK2992020T3 (enExample)
ES (1) ES2777940T3 (enExample)
HU (1) HUE048312T2 (enExample)
IL (1) IL242315B (enExample)
MX (1) MX370173B (enExample)
PL (1) PL2992020T3 (enExample)
PT (1) PT2992020T (enExample)
WO (1) WO2014179759A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279432A (zh) * 2016-08-10 2017-01-04 中山大学 一种vc‑car分子及在清除hiv‑1感染细胞中的应用
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
CN109195985A (zh) * 2016-03-23 2019-01-11 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） Pd-1和4-1bb的融合蛋白
CN110636855A (zh) * 2017-03-28 2019-12-31 俄亥俄州创新基金会 人pd1肽疫苗及其用途
WO2020025039A1 (zh) * 2018-08-03 2020-02-06 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
CN111107855A (zh) * 2017-08-06 2020-05-05 强普生技股份有限公司 医药试剂盒及其用途
CN112442126A (zh) * 2019-09-04 2021-03-05 杭州中柏济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
WO2022063302A1 (zh) * 2020-09-25 2022-03-31 克莱格医学有限公司 免疫细胞活性调节
CN116410331A (zh) * 2021-12-31 2023-07-11 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115028735A (zh) * 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
CN114085856A (zh) * 2014-12-05 2022-02-25 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
WO2016109668A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
HK1245287A1 (zh) 2015-01-26 2018-08-24 The University Of Chicago IL13RAα2结合剂和其在癌症治疗中的用途
JP6849600B6 (ja) * 2015-01-29 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ キメラ抗原受容体、組成物及び方法
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
HK1250918A1 (zh) 2015-04-06 2019-01-18 Cytoimmune Therapeutics, Inc. 用於胶质母细胞瘤的egfr导向的car疗法
EP3298046B1 (en) * 2015-05-20 2025-02-12 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
JP2018517415A (ja) * 2015-06-10 2018-07-05 ナントクエスト インコーポレイテッド がんを処置するための改変ｎｋ−９２細胞
JP7010487B2 (ja) 2015-08-17 2022-03-03 ソウル大学校産学協力団 抗コチニン抗体が連結したキメラ抗原受容体およびその使用
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
TW201740958A (zh) * 2016-01-15 2017-12-01 依圖比克斯公司 用於t細胞免疫療法之方法及組合物
WO2017130223A2 (en) 2016-01-29 2017-08-03 Virocan Therapeutics Pvt. Ltd. A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
JP7145761B2 (ja) * 2016-04-22 2022-10-03 クレイジュ・メディカル・カンパニー・リミテッド 細胞免疫療法の組成物および方法
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
EP3558368B1 (en) 2016-12-23 2025-11-12 MacroGenics, Inc. Adam9-binding molecules, and methods of use thereof
CN110475857B (zh) 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
BR112019019606A2 (pt) * 2017-03-20 2020-04-14 Hope City células t modificadas pelo receptor de antígeno quimérico direcionado a cs1
EP3592854A1 (en) 2017-04-13 2020-01-15 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
CN111212663A (zh) * 2017-07-07 2020-05-29 H·李·莫菲特癌症中心研究所公司 具有突变的cd28共刺激性结构域的嵌合抗原受体
WO2019014624A1 (en) * 2017-07-14 2019-01-17 The Johns Hopkins University Engineered tsc2
AU2018346719A1 (en) * 2017-10-06 2020-04-23 Oslo Universitetssykehus Hf Chimeric antigen receptors
US12077598B2 (en) 2018-03-16 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 phosphorylation sites
CN112566643A (zh) 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
EP3818148A4 (en) * 2018-07-05 2022-09-28 Emory University TRANSDUCTION OF CONGENITAL IMMUNE COMPETENT CELLS USING AAV6
EP3894011B1 (en) 2018-12-11 2025-09-17 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
CN116200342A (zh) 2019-04-03 2023-06-02 精密生物科学公司 包含microRNA适应的shRNA（shRNAmiR）的遗传修饰的免疫细胞
EP3983538A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CN114729383A (zh) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 重组ad35载体及相关基因疗法改进
US12139544B2 (en) * 2019-11-08 2024-11-12 Mayo Foundation For Medical Education And Research EphA3 directed CAR-T cells for treatment of tumors
EP4172189A1 (en) * 2020-06-29 2023-05-03 Julius-Maximilians-Universität Würzburg Slamf7 cars
CN114286691B (zh) * 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 Cs1-抗体和抗cs1-car-t细胞
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
EP4626924A1 (en) * 2022-12-02 2025-10-08 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064083A1 (en) * 2003-05-08 2012-03-15 Abbott Biotherapeutics Corp. Therapeutic use of anti-cs1 antibodies
WO2012071411A3 (en) * 2010-11-22 2012-08-16 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
CN1423700A (zh) * 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
KR20110096536A (ko) 2008-10-31 2011-08-30 애보트 바이오테라퓨틱스 코포레이션 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2556085A2 (en) 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6053688B2 (ja) * 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
MX2014005957A (es) 2011-11-16 2015-02-04 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico.
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
BR112015013193A2 (pt) 2012-12-07 2017-07-11 Solazyme Inc ácido nucleico recombinante, cassete de expressão, célula, método para obter óleo microbiano, óleo microbiano, e, método para obter óleo microbiano.
CN103224561A (zh) 2013-01-16 2013-07-31 天津大学 葡萄球菌肠毒素小分子抗体及制备方法及用途
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN115028735A (zh) * 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
CN112118850A (zh) * 2018-03-16 2020-12-22 赛通免疫治疗公司 双特异性抗体car细胞免疫疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064083A1 (en) * 2003-05-08 2012-03-15 Abbott Biotherapeutics Corp. Therapeutic use of anti-cs1 antibodies
JP2012121878A (ja) * 2003-05-08 2012-06-28 Abbott Biotherapeutics Corp 抗ｃｓ１抗体の治療的使用
WO2012071411A3 (en) * 2010-11-22 2012-08-16 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ATTIANESE，G.M.P.G等: "A new Chimeric Antigen Receptor (CAR) targeting the CD23 antigen expressed by Chronic Lymphocytic Leukemia (B-CLL) cells", 《BLOOD》 *
BURNS W R等: "A high molecular weight-melanoma associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas", 《CANCER RESEARCH》 *
DON M.BENSON JR等: "CS1-directed monoclonal antibody therapy for multiple myeloma", 《JOURNAL OF CLINICAL ONCOLOGY OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY》 *
JAKUBOWIAK A J等: "Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma", 《JOURNAL OF CLINICAL ONCOLOGY》 *
JENA B等: "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", 《BLOOD》 *
S LONIAL等: "Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma", 《JOURNAL OF CLINICAL ONCOLOGY》 *
YAYA CHU等: "Genetically engineered natural killer (NK) cell immunotherapy for poor risk B-cell (CD20+) leukemia and lymphoma (L/L）", 《CANCER RESEARCH》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195985A (zh) * 2016-03-23 2019-01-11 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） Pd-1和4-1bb的融合蛋白
US11365237B2 (en) 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
CN106279432B (zh) * 2016-08-10 2019-09-20 深圳市再生之城生物医药技术有限公司 一种vc-car分子及在清除hiv-1感染细胞中的应用
CN106279432A (zh) * 2016-08-10 2017-01-04 中山大学 一种vc‑car分子及在清除hiv‑1感染细胞中的应用
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
CN110636855A (zh) * 2017-03-28 2019-12-31 俄亥俄州创新基金会 人pd1肽疫苗及其用途
CN111107855A (zh) * 2017-08-06 2020-05-05 强普生技股份有限公司 医药试剂盒及其用途
WO2020025039A1 (zh) * 2018-08-03 2020-02-06 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
CN112442126A (zh) * 2019-09-04 2021-03-05 杭州中柏济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
WO2022063302A1 (zh) * 2020-09-25 2022-03-31 克莱格医学有限公司 免疫细胞活性调节
CN116410331A (zh) * 2021-12-31 2023-07-11 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用

Also Published As

Publication number Publication date
KR20160003071A (ko) 2016-01-08
KR102098985B1 (ko) 2020-04-09
ES2777940T3 (es) 2020-08-06
US11845794B2 (en) 2023-12-19
BR112015027567B1 (pt) 2024-02-20
US10227409B2 (en) 2019-03-12
WO2014179759A1 (en) 2014-11-06
AU2014259675A1 (en) 2015-11-12
EP2992020A1 (en) 2016-03-09
EP3663320A1 (en) 2020-06-10
US20170320941A1 (en) 2017-11-09
PT2992020T (pt) 2020-02-28
CN115028735A (zh) 2022-09-09
EP2992020B1 (en) 2020-01-15
HK1218925A1 (en) 2017-03-17
AU2019203823A1 (en) 2019-06-20
MX2015015182A (es) 2016-05-05
JP6856188B2 (ja) 2021-04-07
IL242315B (en) 2020-07-30
BR112015027567A2 (pt) 2017-12-05
JP2021177771A (ja) 2021-11-18
US20160075784A1 (en) 2016-03-17
PL2992020T3 (pl) 2020-06-01
JP2019146579A (ja) 2019-09-05
AU2019203823B2 (en) 2021-05-13
HUE048312T2 (hu) 2020-07-28
JP7221338B2 (ja) 2023-02-13
JP2016524598A (ja) 2016-08-18
EP2992020A4 (en) 2016-12-28
DK2992020T3 (da) 2020-02-10
MX370173B (es) 2019-12-04
US20200002418A1 (en) 2020-01-02
AU2014259675B2 (en) 2019-05-02
US10358494B2 (en) 2019-07-23
CA2910666A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
JP7221338B2 (ja) Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞
US20230303653A1 (en) Compositions and methods of chimeric autoantibody receptor t cells
US20220135699A1 (en) Chimeric antigen receptor comprising interleukin-15 intracellular domain and uses thereof
US11851491B2 (en) Compositions and methods for TCR reprogramming using fusion proteins
JP2021522790A (ja) ホスホリパーゼａ２受容体キメラ自己受容体ｔ細胞の組成物および方法
CN114929341A (zh) 用于治疗髓系恶性肿瘤的嵌合抗原受体
CA2910666C (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
WO2026003364A1 (en) Chimeric coreceptors
HK1218925B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160302

RJ01 Rejection of invention patent application after publication